National Research Corporation (NRC) is a noteworthy player in the healthcare sector, specializing in health information services. With a market capitalization of approximately $279.37 million, NRC is a prominent provider of analytics and insights designed to enhance both patient and employee experiences within healthcare organizations. Founded in 1981 and based in Lincoln, Nebraska, NRC offers a plethora of subscription-based solutions that deliver actionable data to healthcare providers, allowing them to improve on various crucial aspects of care and engagement.
The company’s current stock price sits at $12.33, reflecting a modest price change of 0.02% recently. However, over the past year, NRC’s stock has experienced a significant range, fluctuating between $10.13 and $22.48. This volatility could be indicative of the challenges and opportunities faced by the healthcare analytics industry in adapting to shifting market dynamics and technological advancements.
A standout figure for NRC is its impressive Return on Equity (ROE) of 51.24%. This metric suggests that the company is highly efficient in generating profits from its equity, a sign of robust management and potentially attractive to investors seeking strong operational performance. However, it’s important to note that the company’s revenue growth has contracted by 4.60%, which may raise concerns about its ability to expand its market influence in the near term.
When it comes to dividends, NRC offers a yield of 4.55%, though the payout ratio stands at a striking 104.00%. This suggests that the company is distributing more in dividends than it earns, which could be unsustainable in the long run if not balanced by future earnings growth or operational efficiency improvements.
From an analyst perspective, NRC currently has no buy, hold, or sell ratings. This absence of coverage might signal that the stock is flying under the radar or that analysts are uncertain about its future trajectory. Additionally, technical indicators such as a 50-day moving average of 18.26 and a 200-day moving average of 15.51 highlight that the stock is trading below these averages, potentially indicating a bearish trend. The Relative Strength Index (RSI) of 26.33 further points to the stock being in oversold territory, which might present a buying opportunity for contrarian investors.
NRC’s innovative offerings, like the Huey AI engine, underscore its commitment to leveraging technology in enhancing healthcare experiences. This focus on AI and digital platforms could position the company well in an industry that increasingly values tech-driven solutions.
For investors, National Research Corporation presents a mixed bag of opportunities and risks. Its high ROE and dividend yield are attractive, yet the revenue decline and high payout ratio warrant caution. As the healthcare analytics sector evolves, NRC’s ability to innovate and adapt will be crucial in determining its future success and shareholder value.
